Current Report Filing (8-k)
December 15 2014 - 8:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): December
10, 2014
BioTime,
Inc.
(Exact name of registrant as specified in its charter)
California
|
1-12830
|
94-3127919
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address of principal executive offices)
(510)
521-3390
(Registrant's telephone number, including area
code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward-Looking Statements
Any statements that are not historical fact (including, but not
limited to statements that contain words such as “may, “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should also be considered to be forward-looking statements. Additional
factors that could cause actual results to differ materially from the
results anticipated in these forward-looking statements are contained in
BioTime’s periodic reports filed with the SEC under the heading “Risk
Factors” and other filings that BioTime may make with the Securities and
Exchange Commission. Undue reliance should not be placed on these
forward-looking statements which speak only as of the date they are
made, and the facts and assumptions underlying these statements may
change. Except as required by law, BioTime disclaims any intent or
obligation to update these forward-looking statements.
The information contained in Item 7 of this Report shall be deemed
“furnished” and not “filed” under the Securities Exchange Act of 1934,
as amended.
Section 7 - Regulation FD
Item 7.01 - Regulation FD Disclosure
On December 10th, 2014 our subsidiary ES Cell International Pte Ltd.
(“ESI”) signed a Cross-License Agreement with GE Healthcare (“GEHC”)
through which GEHC received co-exclusive rights to use and sublicense to
third parties ESI’s stem cell patents in the field of cell-based
assays. In exchange, ESI received from GEHC a non-exclusive, world-wide
sublicense to use certain patents to develop, manufacture, use, market
and sell cell-based-assays.
The field of cell-based assays encompasses the use of human embryonic
stem cells and their derivatives for drug discovery and development,
drug monitoring, drug toxicology testing, and consumer products
testing. The field of stem cell assay products is important to
developers of pharmaceuticals and other healthcare products as a means
to determine whether their potential new products may prove to be
hazardous due to unexpected toxicity to the heart, liver, or other
tissues. The field is populated by customers that include major
pharmaceutical companies, biotech companies and consumer product
companies, among others.
Pursuant to the Cross-License Agreement, ESI, in certain circumstances,
received a right to further sublicense the rights it obtained under the
Cross-License Agreement. ESI retains its existing rights for the use of
embryonic stem cells for therapeutic, diagnostic and basic
research. GEHC received a right of first negotiation to manufacture
cell assay products developed by ESI should ESI decide to have such
products manufactured by a third party.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
BIOTIME, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
December
15, 2014
|
By:
|
/s/ Michael D. West
|
|
|
|
|
Chief Executive Officer
|
3
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024